Abstract
We are exploring a novel experimental treatment for malignant brain tumors utilizing a genetically engineered, attenuated, replication-competent herpes simplex virus type 1 (HSV-1). Our previous studies demonstrated that a thymidine kinase-deficient HSV-1 mutant (dlsptk) could destroy human glioma cells in an animal brain tumor model. This HSV-1 mutant has a 360-base pair deletion in the thymidine kinase gene, allowing for replication in dividing tumor cells but not in nondividing cells. We hypothesized that such HSV-1 mutants might replicate in actively growing tumor cells and effectively kill malignant brain tumors while sparing normal brain cells. So that this therapy could become an effective clinical choice, we have examined different HSV-1 mutants. We tested a ribonucleotide reductase-deficient mutant as an experimental treatment for malignant brain tumors. The HSV-1 mutant hrR3, containing Escherichia coli lacZ gene in the ICP6 gene that encodes the large subunit of ribonucleotide reductase, is hypersensitive to antiherpetic agents acyclovir and ganciclovir while dlsptk is resistant. We have demonstrated that hrR3 destroyed human glioblastoma cells in vitro and in vivo as well as dlsptk. These results have stimulated interest in the possible clinical trial of hrR3 for the treatment of malignant brain tumors.
Key words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Walker MD, Green SB, Byar DP (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329
Mahaley MS, Mettlin C, Natarajan N, et al (1989) National survey of patterns of care for brain-tumor patients. J Neurosurg 71:826–836
Kim TS, Halliday AL, Headley-Whyte ET, et al (1991) Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 74:27–37
Schoenberg BS (1983) The epidemiology of central nervous system tumors. In: Wlaker MD (ed) Oncology of the nervous system. Nijhoff, Boston, pp 1–30
Taylor MW, Cordell B, Souhrada M, et al (1971) Viruses as an aid to cancer therapy: regression of solid and ascites tumors in rodents after treatment with bovine enterovirus. Proc Natl Acad Sci USA 68:836–840
Kobayashi H (1979) Viral xenogenization of intact tumor cells. Adv Cancer Res 30:279–299
Cassel WA, Murray DR, Phillips HS (1983) A phase II study on the postsurgical management of stage II malignant melanoma with a newcastle disease virus oncolysate. Cancer 52:856–860
Short MP, Choi BC, Lee JK, et al (1990) Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 27:427–439
Takamiya Y, Short MP, Ezzenddine ZD, et al (1992) Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 33:493–503
Takamiya Y, Short MP, Moolten FL, et al (1993) An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 79:104–110
Culver KW, Ram Z, Walbridge S, et al (1992) In vivo gene transfer with retroviral vectorproducer cells for treatment of experimental brain tumors. Science 256:1550–1552
Ram Z, Culver KW, Walbridge S, et al (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53:83–88
Martuza RL, Malick A, Markert JM, et al (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854–856
Markert JM, Coen DM, Malick A, et al (1992) Expanded spectrum of viral therapy in the treatment of nervous system tumors. J Neurosurg 77:590–594
Mineta T, Rabkin SD, Martuza RL (1994) Treatment of malignant glioma using ganciclovirhypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54:3963–3966
Coen DM, Kosz-Vnenchak M, Jacobson JG, et al (1989) Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Ac-a d Sci USA 86:4736–4740
Field HJ, Wildy P (1978) The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg Camb (Lond) 81:267–277
Field HJ, Darby G (1980) Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob Agents Chemother 17:209–216
Duita BM (1983) Ribonucleotide reductase induced by herpes simplex virus has a virusspecific constituent. J Gen Virol 64:513–521
Thelander L, Reichard P (1979) Reduction of ribonucleotide. Annu Rev Biochem 48:133–158
Preston VG, Palfreyman JW, Duita BM (1984) Identification of a herpes simplex virus type 1 polypeptide which is a component of the virus-induced ribonucleotide reductase. J Gen Virol 65:1457–1466
Goldstein DJ, Weller SK (1988) Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62:196–205
Goldstein DJ, Weller SK (1988) Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166:41–51
Jacobson JG, Leib DA, Goldstein DJ, et al (1989) A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivable latent infections of mice and for replication in mouse cells. Virology 173:276–283
Cameron JM, McDougall I, Marsden HS, et al (1988) Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J Gen Virol 69:2607–2612
Coen DM, Goldstein DJ, Weller SK (1989) Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob Agents Chemother 33:1395–1399
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Japan
About this paper
Cite this paper
Mineta, T., Rabkin, S.D., Martuza, R.L. (1996). Experimental Therapy for Malignant Brain Tumors Using Genetically Engineered Herpes Simplex Virus Type 1. In: Nagai, M. (eds) Brain Tumor. Springer, Tokyo. https://doi.org/10.1007/978-4-431-66887-9_42
Download citation
DOI: https://doi.org/10.1007/978-4-431-66887-9_42
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-66889-3
Online ISBN: 978-4-431-66887-9
eBook Packages: Springer Book Archive